These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 15328125)

  • 1. SRI-286, a thiosemicarbazole, in combination with mefloquine and moxifloxacin for treatment of murine Mycobacterium avium complex disease.
    Bermudez LE; Kolonoski P; Seitz LE; Petrofsky M; Reynolds R; Wu M; Young LS
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3556-8. PubMed ID: 15328125
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thiosemicarbazole (thiacetazone-like) compound with activity against Mycobacterium avium in mice.
    Bermudez LE; Reynolds R; Kolonoski P; Aralar P; Inderlied CB; Young LS
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2685-7. PubMed ID: 12878542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mefloquine, moxifloxacin, and ethambutol are a triple-drug alternative to macrolide-containing regimens for treatment of Mycobacterium avium disease.
    Bermudez LE; Kolonoski P; Petrofsky M; Wu M; Inderlied CB; Young LS
    J Infect Dis; 2003 Jun; 187(12):1977-80. PubMed ID: 12792877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.
    Bermudez LE; Inderlied CB; Kolonoski P; Petrofsky M; Aralar P; Wu M; Young LS
    Antimicrob Agents Chemother; 2001 Jan; 45(1):217-22. PubMed ID: 11120969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of refractory disseminated Mycobacterium avium complex infection with the addition of linezolid and mefloquine.
    Nannini EC; Keating M; Binstock P; Samonis G; Kontoyiannis DP
    J Infect; 2002 Apr; 44(3):201-3. PubMed ID: 12099753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro and in vivo activities of novel fluoroquinolones alone and in combination with clarithromycin against clinically isolated Mycobacterium avium complex strains in Japan.
    Kohno Y; Ohno H; Miyazaki Y; Higashiyama Y; Yanagihara K; Hirakata Y; Fukushima K; Kohno S
    Antimicrob Agents Chemother; 2007 Nov; 51(11):4071-6. PubMed ID: 17709469
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of (+)-erythro-mefloquine as an active enantiomer with greater efficacy than mefloquine against Mycobacterium avium infection in mice.
    Bermudez LE; Inderlied CB; Kolonoski P; Chee CB; Aralar P; Petrofsky M; Parman T; Green CE; Lewin AH; Ellis WY; Young LS
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4202-6. PubMed ID: 22615290
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic/pharmacodynamic-based treatment of disseminated Mycobacterium avium.
    Deshpande D; Gumbo T
    Future Microbiol; 2011 Apr; 6(4):433-9. PubMed ID: 21526944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of mouse models of Mycobacterium avium complex infection and evaluation of drug combinations.
    Andréjak C; Almeida DV; Tyagi S; Converse PJ; Ammerman NC; Grosset JH
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2129-35. PubMed ID: 25624335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of refractory Mycobacterium avium complex lung disease with a moxifloxacin-containing regimen.
    Koh WJ; Hong G; Kim SY; Jeong BH; Park HY; Jeon K; Kwon OJ; Lee SH; Kim CK; Shin SJ
    Antimicrob Agents Chemother; 2013 May; 57(5):2281-5. PubMed ID: 23478956
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mefloquine is active in vitro and in vivo against Mycobacterium avium complex.
    Bermudez LE; Kolonoski P; Wu M; Aralar PA; Inderlied CB; Young LS
    Antimicrob Agents Chemother; 1999 Aug; 43(8):1870-4. PubMed ID: 10428905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of moxifloxacin or gatifloxacin as prophylaxis against experimental murine Brucella melitensis infection.
    Atkins HS; Spencer S; Brew SD; Laws TR; Thirlwall RE; MacMillan AP; Brooks TJ; Simpson AJ
    Int J Antimicrob Agents; 2009 Nov; 34(5):471-3. PubMed ID: 19682862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Moxifloxacin pharmacokinetics/pharmacodynamics and optimal dose and susceptibility breakpoint identification for treatment of disseminated Mycobacterium avium infection.
    Deshpande D; Srivastava S; Meek C; Leff R; Hall GS; Gumbo T
    Antimicrob Agents Chemother; 2010 Jun; 54(6):2534-9. PubMed ID: 20385862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Moxifloxacin and hepatic toxicity].
    Franco Hidalgo S; Prieto de Paula JM; García Lorenzo R; Salado Valdivieso I
    Gastroenterol Hepatol; 2009 Dec; 32(10):719-20. PubMed ID: 19664854
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparative in vitro and in vivo antimicrobial activities of sitafloxacin, gatifloxacin and moxifloxacin against Mycobacterium avium.
    Sano C; Tatano Y; Shimizu T; Yamabe S; Sato K; Tomioka H
    Int J Antimicrob Agents; 2011 Apr; 37(4):296-301. PubMed ID: 21353489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposomal amikacin: improved treatment of Mycobacterium avium complex infection in the beige mouse model.
    Petersen EA; Grayson JB; Hersh EM; Dorr RT; Chiang SM; Oka M; Proffitt RT
    J Antimicrob Chemother; 1996 Nov; 38(5):819-28. PubMed ID: 8961051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Moxifloxacin (Kanavig), ophthalmic administration].
    J Pharm Belg; 2012 Jun; (2):41-2. PubMed ID: 22978015
    [No Abstract]   [Full Text] [Related]  

  • 18. Moxifloxacin-associated neutropenia.
    Berk V; Demiraslan H; Berk E; Karaca H; Inanc M; Bozkurt O; Ozkan M
    Scand J Infect Dis; 2013 May; 45(5):415-6. PubMed ID: 23151058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system.
    Ginsburg AS; Lee J; Woolwine SC; Grosset JH; Hamzeh FM; Bishai WR
    Antimicrob Agents Chemother; 2005 Feb; 49(2):853-6. PubMed ID: 15673788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Perspective on animal models: chronic intracellular infections.
    Young LS; Bermudez LE
    Clin Infect Dis; 2001 Sep; 33 Suppl 3():S221-6. PubMed ID: 11524722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.